Cancer-associated fibroblast
Cancer-associated fibroblasts (CAFs) are activated stromal fibroblasts that reside within the tumor microenvironment and play a central role in promoting malignant progression and therapeutic resistance.
Cancer-associated fibroblasts (CAFs) are activated stromal fibroblasts that reside within the tumor microenvironment and play a central role in promoting malignant progression and therapeutic resistance. These cells arise from mesenchymal lineages within tumor stroma and are phenotypically and functionally distinct from quiescent fibroblasts, characterized by markers such as fibroblast activation protein (fibroblast activation protein alpha (FAP)). CAFs exhibit spatial heterogeneity and display specialized functional states that collectively contribute to multiple aspects of tumor biology, including extracellular matrix remodeling, metabolic reprogramming, and immunosuppression. Their functional impact extends across diverse cancer types—including pancreatic adenocarcinoma, hepatocellular carcinoma, breast cancer, colorectal cancer, and oral squamous cell carcinoma—where they are emerging as key mediators of both tumor progression and resistance to immunotherapy.
The significance of CAFs in cancer biology centers on their multifaceted interactions with both malignant cells and the immune compartment. CAF-derived signaling, metabolic output (such as lactate production through the SDC1-ENO1 axis), and soluble factors shape the immunosuppressive landscape and can reprogram local immune responses through pathways involving tryptophan metabolism and Sting activation. Beyond their role in promoting epithelial-mesenchymal transition and radioresistance, CAFs generate physical and biochemical barriers that limit therapeutic penetration and efficacy of both conventional and immunotherapies, including anti-Programmed cell death 1 (PD-1) approaches. Contemporary therapeutic strategies increasingly target CAFs through multiple modalities—depletion (fibroblast activation protein alpha (FAP)-targeted approaches), normalization, and metabolic reprogramming—reflecting growing recognition that effective cancer treatment may require concurrent manipulation of the stromal compartment alongside direct targeting of tumor cells.
Where the papers sit
13 papers from the last 6 months study cancer-associated fibroblast directly · updated from PubMed 5 Oct 2026
Study type 0 clinical trials · 2 observational · 3 human data · 5 preclinical · 3 unclassified
Themes 3 themes · 1 new direction
-
CAF-Driven Immune Suppression
CAF subtypes are being mapped as active drivers of immune exclusion, metabolic support and chemotherapy resistance in pancreatic and colorectal cancer. CTGF+, THY1 and INHBA+ populations are linked to tumor-stroma crosstalk, EMT, immune suppression and poor prognosis. Mitophagy-competent CAFs support pancreatic chemoresistance by rewiring pyrimidine metabolism, while TGF-beta and endothelial barriers reinforce checkpoint resistance. The direction is toward subtype-selective CAF disruption rather than blanket depletion. Gemcitabine response and checkpoint sensitivity remain key tests, with spatial context refining patient stratification.
7 papers · 53.8%
-
Stromal Therapy Resistance
Stromal heterogeneity and spatial interactions are being linked to resistance in liver cancer, especially hepatocellular carcinoma. WNK4-mediated cysteine-metabolism reprogramming connects stellate-cell biology with anti-PD-1 resistance and progression. Targeting both tumor cells and stroma is proposed for drug-resistant disease, exemplified by dual-cargo polymeric micelles. Whether these mechanisms generalize beyond liver cancer remains open.
3 papers · 23.1%
-
CAF Heterogeneity and Prognosis
Distinct CAF sources and states are repeatedly associated with worse prognosis, invasion, or reduced treatment efficacy across glioblastoma and oral cancer. Pericyte-derived CAFs expand after chemoradiotherapy, while mixed populations emerging during FAP-CD3 engagement can blunt therapy. Invasion-front CAFs provide a prognostic signal in oral squamous cell carcinoma. The recurring question is whether CAF heterogeneity can guide patient selection and improve stromal-targeted treatment.
3 papers · 23.1%
In glioblastoma, cancer-associated fibroblasts may be a pericyte-derived transcriptional state rather than a conventional fibroblast population
The glioblastoma study, examining single-cell and bulk datasets to determine the identity and origin of CAFs in a brain tumor, challenges the assumption that CAFs are a distinct fibroblast population: it found a continuous transcriptional spectrum linking endothelial cells, pericytes, and CAFs, with pericytes the most likely source, despite the absence of fibroblasts from normal brain parenchyma. This assigns CAFs a role as a perivascular cell state that can emerge in the tumor context, changing interpretation of CAF signatures and the rationale for targeting them in glioblastoma 42721145Sep.
Papers
The 13 papers from the last 6 months that study cancer-associated fibroblast directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
CAF-Driven Immune Suppression (7)
- A recurrent cancer-associated fibroblast/TGF-beta/endothelial barrier direction is associated with immune exclusion and checkpoint resistance in bladder cancer: a public multi-cohort transcriptomic study. PloS one · 22 Sept 2026 PMID 42771603
- Targeting CTGF+ cancer-associated fibroblasts disrupts tumor-stroma crosstalk in pancreatic ductal adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America · 2 Sept 2026 PMID 42685072
- Integrated Transcriptomic Analysis and Machine Learning Identify THY1 as a Key Regulator of Cancer-Associated Fibroblast Infiltration, Promoting Malignant Progression and Immune Escape in Gastric Cancer. Journal of gastroenterology and hepatology · 22 Aug 2026 PMID 42629612
- Improving pancreatic adenocarcinoma prognosis models through ligand receptor interactions and histopathological integration. Journal of translational medicine · 3 Jul 2026 PMID 42399741
- Mitophagy-Competent Cancer-Associated Fibroblasts Fuel Chemoresistance by Rewiring Pyrimidine Metabolism in Pancreatic Cancer. Cancer research · 27 May 2026 PMID 42202065
- Spatial multi-omics defines cancer-associated fibroblasts subtype gradients driving metabolic support and immune remodeling in pancreatic ductal adenocarcinoma. Cancer letters · 17 May 2026 PMID 42144098
- A multi-omics dissection of INHBA+ CAF-mediated epithelial-mesenchymal transition and immune suppression in colorectal cancer. Journal of translational medicine · 16 May 2026 PMID 42143353
Stromal Therapy Resistance (3)
- Dynamic subpopulations and spatial interactions of hepatic stellate cells and cancer-associated fibroblasts in liver cancer. Acta biochimica et biophysica Sinica · 14 Aug 2026 PMID 42599778
- Dual-cargo polymeric micelles with tumor-cell/stroma dual-targeting for synergistic eradication of drug-resistant breast cancer. Biomaterials science · 10 Aug 2026 PMID 42572978
- WNK4 Enhances Anti-PD-1 Resistance and Promotes Tumor Progression in Hepatocellular Carcinoma by Reprogramming Cysteine Metabolism in Cancer-Associated Fibroblasts. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 8 Jun 2026 PMID 42253146
CAF Heterogeneity and Prognosis (3)
- Pericyte-derived cancer-associated fibroblasts correlate with poor survival and are enriched after chemoradiotherapy in glioblastoma. PloS one · 10 Sept 2026 PMID 42721145
- Emergence of a mixed CAF population by FAP-CD3 T-cell engager limits therapeutic efficacy. Journal for immunotherapy of cancer · 3 Jul 2026 PMID 42398971
- Cancer-Associated Fibroblasts in Invasion Front Can be a Prognostic Predictor for Oral Squamous Cell Carcinoma. Pathology international · 1 Jun 2026 PMID 42219817
By study type
Observational studies and case reports (2)
- A recurrent cancer-associated fibroblast/TGF-beta/endothelial barrier direction is associated with immune exclusion and checkpoint resistance in bladder cancer: a public multi-cohort transcriptomic study. PloS one · 22 Sept 2026 PMID 42771603
- Cancer-Associated Fibroblasts in Invasion Front Can be a Prognostic Predictor for Oral Squamous Cell Carcinoma. Pathology international · 1 Jun 2026 PMID 42219817
Human data, design not indexed (3)
- Pericyte-derived cancer-associated fibroblasts correlate with poor survival and are enriched after chemoradiotherapy in glioblastoma. PloS one · 10 Sept 2026 PMID 42721145
- Integrated Transcriptomic Analysis and Machine Learning Identify THY1 as a Key Regulator of Cancer-Associated Fibroblast Infiltration, Promoting Malignant Progression and Immune Escape in Gastric Cancer. Journal of gastroenterology and hepatology · 22 Aug 2026 PMID 42629612
- Spatial multi-omics defines cancer-associated fibroblasts subtype gradients driving metabolic support and immune remodeling in pancreatic ductal adenocarcinoma. Cancer letters · 17 May 2026 PMID 42144098
Preclinical: animal, cell and lab studies (5)
- Targeting CTGF+ cancer-associated fibroblasts disrupts tumor-stroma crosstalk in pancreatic ductal adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America · 2 Sept 2026 PMID 42685072
- Dual-cargo polymeric micelles with tumor-cell/stroma dual-targeting for synergistic eradication of drug-resistant breast cancer. Biomaterials science · 10 Aug 2026 PMID 42572978
- Emergence of a mixed CAF population by FAP-CD3 T-cell engager limits therapeutic efficacy. Journal for immunotherapy of cancer · 3 Jul 2026 PMID 42398971
- WNK4 Enhances Anti-PD-1 Resistance and Promotes Tumor Progression in Hepatocellular Carcinoma by Reprogramming Cysteine Metabolism in Cancer-Associated Fibroblasts. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 8 Jun 2026 PMID 42253146
- Mitophagy-Competent Cancer-Associated Fibroblasts Fuel Chemoresistance by Rewiring Pyrimidine Metabolism in Pancreatic Cancer. Cancer research · 27 May 2026 PMID 42202065
Unclassified: not yet indexed with MeSH (3)
- Dynamic subpopulations and spatial interactions of hepatic stellate cells and cancer-associated fibroblasts in liver cancer. Acta biochimica et biophysica Sinica · 14 Aug 2026 PMID 42599778
- Improving pancreatic adenocarcinoma prognosis models through ligand receptor interactions and histopathological integration. Journal of translational medicine · 3 Jul 2026 PMID 42399741
- A multi-omics dissection of INHBA+ CAF-mediated epithelial-mesenchymal transition and immune suppression in colorectal cancer. Journal of translational medicine · 16 May 2026 PMID 42143353
Written from 13 PubMed abstracts, each one listed by PMID above. Published: 2026-06-16. Last written: 2026-09-24 by GPT. Drafted by language models from published abstracts; not medical advice.